Corporate ActionOct 6, 2026, 04:31 PM
Sonoma Pharmaceuticals Adopts Rights Agreement to Protect NOLs
AI Summary
Sonoma Pharmaceuticals, Inc. has entered into a new Section 382 rights agreement, effective October 6, 2026, to safeguard its Net Operating Loss (NOL) carryforwards and other tax benefits. This agreement replaces an expiring one and will issue preferred stock purchase rights to shareholders of record on October 13, 2026. These rights are intended to prevent an 'ownership change' that could significantly limit the company's ability to utilize its substantial NOLs, which are considered a valuable asset. The rights will become exercisable under specific conditions related to changes in beneficial ownership of the company's common stock.
Key Highlights
- Sonoma Pharmaceuticals adopted a Section 382 rights agreement to protect shareholder value and its Net Operating Loss (NOL) carryforwards.
- The new rights agreement replaces the previous one expiring on October 18, 2026.
- Each common stock holder will receive one preferred stock purchase right (Right) for each share held as of October 13, 2026.
- Each Right allows the holder to purchase one one-thousandth of a share of Series B Preferred Stock for $10.00.
- The Rights become exercisable if a person or group acquires 4.99% or more of the company's common stock, or if a 'Grandfathered Person' exceeds their ownership threshold.
- The Rights Agreement is designed to prevent an 'ownership change' as defined by Section 382 of the Internal Revenue Code, which could limit the use of NOLs.
- The Rights will expire on October 6, 2036, unless earlier redeemed or exhausted.
Price Impact
More from SNOA